Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2001 3
2002 1
2004 4
2005 1
2006 3
2007 1
2008 3
2009 4
2010 7
2011 2
2012 13
2013 14
2014 9
2015 11
2016 9
2017 8
2018 6
2019 5
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 30642877

92 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.
Estrada CC, Maldonado A, Mallipattu SK. Estrada CC, et al. J Am Soc Nephrol. 2019 Feb;30(2):187-200. doi: 10.1681/ASN.2018080853. Epub 2019 Jan 14. J Am Soc Nephrol. 2019. PMID: 30642877 Free PMC article. Review.
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Virgili G, et al. Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5. Cochrane Database Syst Rev. 2017. PMID: 28639415 Free PMC article. Updated. Review.
The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC, Socinski MA. Villaruz LC, et al. Curr Oncol Rep. 2015 Jun;17(6):26. doi: 10.1007/s11912-015-0448-y. Curr Oncol Rep. 2015. PMID: 25947099 Free PMC article. Review.
Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.
Figueroa MS, Contreras I. Figueroa MS, et al. Drugs. 2012 Nov 12;72(16):2063-71. doi: 10.2165/11640820-000000000-00000. Drugs. 2012. PMID: 23061805
Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J, Desai J. Tie J, et al. Crit Rev Oncog. 2012;17(1):51-67. doi: 10.1615/critrevoncog.v17.i1.50. Crit Rev Oncog. 2012. PMID: 22471664 Review.
Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
Kim J, Hwang J, Jeong H, Song HJ, Shin J, Hur G, Park YW, Lee SH, Kim J. Kim J, et al. Epigenetics. 2012 Feb;7(2):191-200. doi: 10.4161/epi.7.2.18973. Epigenetics. 2012. PMID: 22395469
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ. Barr MP, et al. Mol Cancer. 2015 Feb 20;14:45. doi: 10.1186/s12943-015-0310-8. Mol Cancer. 2015. PMID: 25889301 Free PMC article.
Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR. Sharma T, et al. Mini Rev Med Chem. 2013 Apr;13(4):530-40. doi: 10.2174/1389557511313040006. Mini Rev Med Chem. 2013. PMID: 23317499 Review.
Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
Bandello F, Cicinelli MV, Parodi MB. Bandello F, et al. Curr Pharm Des. 2015;21(32):4731-7. doi: 10.2174/1381612821666150909095756. Curr Pharm Des. 2015. PMID: 26350530 Review.
Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S, Del Monte G, Fratangeli F, Guadagni F, Roselli M, Ferroni P. Riondino S, et al. Cardiovasc Hematol Agents Med Chem. 2017;15(1):3-16. doi: 10.2174/1871525715666170127101605. Cardiovasc Hematol Agents Med Chem. 2017. PMID: 28137223 Review.
92 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page